Published by Josh White on 25th June 2025
(Sharecast News) - Scancell announced on Wednesday that it has started dosing patients in cohort four of its phase 2 'SCOPE' clinical trial, evaluating the intradermal administration and accelerated dosing of its iSCIB1+ immunotherapy for advanced unresectable melanoma.
URL: http://www.digitallook.com/dl/news/story/35174668/...